International research on autism varies due to demographic, with population and government regulation sometimes being a key factor in research tactics and therapeutic treatments. One such case of this is in China, where the One-Child Policy is in effect, and the economy is rapidly expanding.
At ICare4Autism’s International Autism Conference, Dr. Wendy Zhang will discuss how these political and economical factors have affected autism research and the treatment of those affected by autism. She will highlight how the perspective of autism may differ in China as opposed to in other countries, including past and present tactics in research and development. This will also include future opportunities in diagnosis and treatment, as well as international research collaborations.
Wenting Zhang is the founder and CEO of SinoCure LLC, and has been an active member in the medical fields of both China and the United States for 24 years. She received her MD degree from Beijing Medical University in 1988 and got her ECFMG Certification in 1996 (MD in USA). She is a key figure in the joint collaboration in Autism and Fragile X Syndrome between UC Davis M.I.N.D. Institute and Beijing Chaoyang Hospital. She also worked at M.I.N.D. Institute, University of California Davis Medical Center on clinical diagnosis and clinical trials for Fragile X Syndrome.